Mesenchymal stem cells (MSCs
INTRODUCTION
Acute cartilage defects may be caused by a comminuted or displaced intra-articular fracture. However, a chronic articular cartilage defect is often caused by matrix degradation during the progression of osteoarthritis (1) (2) (3) . Limited by the intrinsic repairing capacity of cartilage tissue, repairing damaged articular cartilage currently faces major obstacles (4) . Tissue engineering techniquehas provided novel ways to repair cartilage defects (5) . Mesenchymal stem cells (MSCs) have the potential of differentiation into chondrocytes. They are considered as appropriate seed cells in constructing cartilage through tissue engineering (6) . The phenotype of chondrocyte derived from MSCs is difficult to maintain in cartilage reconstruction (7) . Repair cells often lose chondrogenic activity which results in chondrocyte hypertrophy that can affect the formation of stable hyaline cartilage. Therefore, inhibiting chondrocyte hypertrophy in engineered cartilage is an enormous challenge (8) .
Cordycepin, a nucleoside adenosine, is an effective substance of cordyceps (9) . It has been reported that cordycepin possesses various biological functions, including antioxidant, hypolipidemic, and anti-inflammatory activities (10, 11) . A recent study has confirmed that cordycepin may induce leydig tumor cells apoptosis via MAPK/P38 signaling (12) . However, the role of cordycepin in cartilage reconstruction, especially in chondrocyte hypertrophy, remains unclear. Therefore, the objective of this study was to determine the effect of cordycepin on chondrogenesis and chondrocyte hypertrophy in MSCs and ATDC5 cells. Specifically, we determined whether cordycepin could promote chondrogenesis of MSCs. We also determined whether cordycepin could affect chondrocyte hypertrophy of MSCs and murine chondroprogenitor cell line ATDC5 cells at early stage and late stage (13) . Additional, several crucial genes of signaling pathway and transcription factors were examined to explore the molecular mechanisms involved in the effect of cordycepin on chondrocyte hypertrophy.
RESULTS

Cordycepin promotes chondrogenesis of MSCs
MSCs were cultured with basal culture medium for 24, 48, or 72 h and treated with different concentrations of cordycepin followed by CCK8 assays. Results showed that the concentration of cordycepin lower than 1 g/ml had slight effect (P ＞ 0.05) on cell proliferation (Fig. S1A, S1C , S1E). Therefore, cordycepinat concentration of 1 g/ml was regarded as safe and used in this study. After induction by chondrogenic http://bmbreports.org BMB Reports medium containing TGF-3 together with cordycepin for 14 d, compared to control group Toluidine blue staining intensity was increased (P ＜ 0.05) following cordycepin treatment on day 14 (Fig. S2C ). Quantitative PCR (qPCR) analysis revealed that the mRNA levels of chondrogenesis markers including Sox9, Col II, COMP, and Acan in MSCs treated with cordycepin were significantly increased (P ＜ 0.05) compared to group without cordycepin (Fig. 1D, S2B ). After treatment with cordycepin, Sox9 protein level was increased on day 14 and Col II expression was increased on day 7 and 14 ( Fig. 1B, S2E ).
Immunohistochemistry results also revealed that the expression levels of Sox9 and Col II were increased on day 7 and 14 based on the increases of integrated optical densities (Fig.  1C, S2A and S2D). Our data demonstrated that cordycepin promoted chondrogenesis at concentration of 1 g/ml.
Cordycepin inhibits chondrocyte hypertrophy of MSCs at late stage
After induction with chondrogenic differentiation medium containing TGF-3 for 14 d without cordycepin, MSCs were induced by hypertrophic medium containing T3 with cordycepin for another 14 d to examine the effect of cordycepin on chondrocyte hypertrophy. Cordycepinwas used at concentration of 1 g/ml. Toluidine blue staining showed that groups treated with cordycepin had higher (P ＜ 0.05) intensity than control groups ( Fig. 2A, 2C) . Results of qPCR revealed, after cordycepin treatment, the expression levels of hypertrophic marker Col X in groups treated with cordycepin were increased (P ＜ 0.05) on day 17 and 21, MMP13levels were increased (P ＜ 0.05) only on day 17, Runx2 levels were increased (P ＜ 0.05) only on day 21, whereas the expression levels of MMP13 and Runx2 were decreased (P ＜ 0.05) on day 28 compared with those in the control groups (Fig. 2D) . Western blot analysis revealed that the protein levels of Col X and Runx2 in groups treated with cordycepin were not changed on day 17 but decreased on day 21 and 28 compared to those in the control groups (Fig. 2B, S3B ). Immunohistochemistry results revealed that the expression levels of Col X and Runx2 in groups treated with cordycepin on day 21 and 28 were lower than those in the control groups based on integrated optical densities (Fig. S3A, S3C ). These results demonstrated that cordycepin promoted chondrocyte hypertrophy of MSCs at early stage but inhibited chondrocyte hypertrophy of MSCs at late stage.
Cordycepin inhibits chondrocyte hypertrophy of ATDC5 cells at late stage
CCK8 assay was performed to examine the toxicity of cordycepin to ATDC5 cells. Concentration of cordycepin lower than 1 g/ml had no significant (P ＞ 0.05) effect on cell viability ( Fig. S1B , S1D, and S1F).Therefore, cordycepin was used at 1 g/ml for the following experiments to avoid toxicity issue. Previous results showed that cordycepin inhibited MSCs chondrocyte hypertrophy. As a useful tool to study the differentiation of chondrocytes, ATDC5 cells were induced by hypertrophic medium containing T3 with cordycepin for 14 d to examine the effect of cordycepin on chondrocyte hypertrophy. After treatment with cordycepin, compared to control group Toluidine blue staining intensity was increased (P ＜ 0.05) on day 14 ( Fig. S4A) . Results of qPCR revealed that the mRNA levels of hypertrophic markers including MMP13 and Runx2 were increased (P ＜ 0.05) in cells treated with cordycepin on day 3 but decreased (P ＜ 0.05) on day 7 and 14 compared to group without cordycepin treatment ( Fig. S4D ).
After treatment with cordycepin, Runx2 protein level was not changed (P ＞ 0.05) on day 3 but decreased (P ＜ 0.05) on day 7 and 14 compared to group without cordycepin treatment. Col X protein levels in cells treated with cordycepinwere increased (P ＜ 0.05) on day 3 but decreased (P ＜ 0.05) on day 14 compared to group without cordycepin treatment (Fig.  S4E, S4F ). Immunohistochemistry results revealed that the http://bmbreports.org expression levels of Col X and Runx2in cells treated with cordycepin on day 7 and 14 were lower than those in control groups without cordycepin treatment based on integrated optical densities (Fig. S4B, S4C ). Taken together, these results demonstrated that ATDC5 cells hypertrophy were promoted by cordycepin at early stage but inhibited at late stage.
Cordycepin up-regulates BMP signaling during chondrogenesis and down-regulates Notch signaling during hypertrophy differentiation
To explore the molecular mechanisms involved in the effect of cordycepinonTGF-3 induced chondrogenesis of MSCs, we performed qPCR and determined the expression levels of transcriptional factors and key molecules in canonical pathways related to chondrogenesis. After treatment with cordycepin, Hey1 expression was increased on day 3 and 14 compared to that in control groups. Expression levels of Id1 and Id3 were not changed by the treatment of cordycepin. However, Id2 expression was increased in treatment groups on day 14 compared to that in control groups. Moreover, the expression of PI3K was increased in the presence of cordycepin on day 3 and 7 whereas Nrf2 expression was decreased following cordycepin treatment on day 3, 7, and 14 ( Fig. 3A) . These results demonstrated that cordycepin promoted MSCs chondrogenesis through activating BMP and Notch signaling pathways. Besides, cordycepin up-regulated PI3K expression but down-regulated Nrf2 expression to facilitate MSCs chondrogenesis.
To further explore the molecular mechanisms, we performed qPCR to screen the expression of transcriptional factors and key molecules in canonical pathways associated with chondrocyte hypertrophy. In MSCs groups treated with cordycepin, the expression of -catenin was increased on day 17 but unchanged on day 21 and day 28. Bapx1 expression was increased on day 28. On the contrary, the expression of PI3K was decreased on day 28. The expression levels of Hey1 and Hes5 (downstream genes in Notch signaling) were decreased on day 28. Hes1 expression was decreased on both day 21 and day 28 compared to that in the control groups (Fig. 3B,  S5A) . These results were similar to those obtained in ATDC5 cells. After treatment with cordycepin, the expression level of -catenin was increased on day 3 but unchanged on day 7 or 14 compared to that in the control groups. Besides, after cordycepin treatment, Hes1 expression was decreased on day 3, 7, and 14, Hes5 expression was decreased on day 7 and 14, and Hey1 expression was decreased only on day 7. The expression of FAK (a positive regulator of chondrocyte hypertrophy) was increased following cordycepin treatment on day 3 but decreased on day 7 and 14. PI3K was the downstream signaling molecule of FAK. Its expression change was consistent with that of FAK (Fig. 3C, S5B ). Taken together, these results indicated that cordycepin up-regulated BMP signaling during chondrogenesis but down-regulated Notch signaling during hypertrophy differentiation.
DISCUSSION
Cordycepin has been considered as an effective antioxidative agent with protective effects on respiratory system (14) , nervous system (15), endocrine system (16), and tumor metastasis (12, 17, 18) . Based on the characteristics of cordycepin, we hypothesized that cordycepin might also have effect on cartilage metabolism. A previous study has shown that cordycepin has protection against inflammatory cytokine inhibition of osteogenic differentiation of human adipose-derived mesenchymal stem cells (19) . A recent study has also demonstrated that cordycepin could prevent oxidative stress-induced inhibition of osteogenesis (20) .
In this study, we revealed that cordycepin had positive effect on TGF-3 induced chondrogenesis of MSCs. Several specific genes related to cartilage such as Sox9 and Col II (21, 22) were examined in this study to explain the phenomenon at molecular level. These genes were up-regulated by cordycepin treatment. We then focused on two important signaling pathways during chondrogenesis: Notch and BMP. Notch signaling in MSCs is necessary for the initiation of chondrogenesis (23, 24) . Besides, inhibitor of DNA binding/differentiation 1 (Id1), Id2, and Id3 are involved in the BMP signaling pathway indispensable for the formation of cartilage following the activation of the Col II gene (25) (26) (27) . Our qPCR results showed that cordycepin could promote Notch signaling pathway during chondrogenesis. However, cordycepin started to show positive effect on BMP signaling pathway on day 14. In other words, BMP signaling was involved in the regulation of cordycepin at late stages of chondrogenic differentiation. During differentiation of MSCs into chondrocytes, the activation of PI3K can positively regulate chondrogenesis (28) (29) (30) . Nrf2 negatively regulates cellular http://bmbreports.org BMB Reports differentiation toward maturation in chondrocytes (31) . We found that cordycepin could facilitate MSCs chondrogenesis by up-regulating PI3K expression while down-regulating Nrf2 expression.
As an important transcription factor in chondrocyte hypertrophy, Runx2 promotes the expressions of MMP13 and Col X, thus disturbing chondrocyte homeostasis. Cordycepin had dual effects on chondrocyte hypertrophy both in MSCs and ATDC5 cells. Expression levels of specific genes related to chondrocyte hypertrophy including Runx2, MMP13, and Col X were tested in this study and results consistently revealed that cordycepin had dual effects. Interestingly, we found that the protein levels of Runx2 and Col X in MSCs were inhibited by cordycepin starting from 21 d while their mRNA levels were inhibited on day 28. Wnt signaling and Notch signaling are reported to have positive effect on chondrocyte hypertrophy during chondrogenesis (32, 33) . Bapx1 can suppress chondrocyte hypertrophy in ATDC5 cells (34) . PI3K-mediated suppression of Bapx1 in chondrocytes also plays a role in the control of cartilage hypertrophy during skeletal development in vertebrates (35) . It is well known that FAK activates multiple integrin-mediated signal transduction pathways such as PI3K/Akt pathway (36) . The expression of FAK is reported to be significantly higher in osteoarthritis chondrocytes compared to normal control group (37) . Therefore, FAK could be a positive regulator of chondrocyte hypertrophy. In MSCs, cordycepin promoted chondrocyte hypertrophy through Wnt signaling and inhibited chondrocyte hypertrophy through Notch signaling. The expression of PI3K was decreased following cordycepin treatment on day 28 whereas the expression of Bapx1 was increased. Therefore, cordycepin reduced the inhibitory effect of PI3K to Bapx1, thus inhibiting chondrocyte hypertraophy at late stage. As for ATDC5 cells, Wnt and Notch signaling pathways were involved in the regulation of cordycepin at early stage and late stage of chondrocyte hypertrophy, respectively. With cordycepin treatment, the expression of FAK and PI3K were increased at early stage of chondrocyte hypertrophy but decreased at late stage of chondrocyte hypertrophy. Hence, cordycepin regulated the promoting role of FAK on PI3K and inhibited chondrocyte hypertrophy.
Chondrocyte homeostasis is critical for the stability of tissue engineered cartilage (38) . The effect of cordycepin on chondrogenesis and chondrocyte hypertrophy of MSCs might provide us new insights (Fig. 4) . Due to its promoting effect on chondrogenesis, cordycepin can facilitate seed cells differentiation towards chondrocytes to accelerate cartilage repair. In addition, cordycepin can reduce degradation of cartilage matrix to balance anabolic and catabolic cellular activity of repair cells. These data indicate that cordycepin might have potential clinical application to modulate cartilage homeostasis and reconstruct cartilage.
MATERIALS AND METHODS
Cell culture
C3H10T1/2 mesenchymal stem cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). ATDC5 cells were obtained from RIKEN cell Bank (Tsukuba, Japan). These cells were cultured in DMEM-F12 (Gibco Life Technology, Gaithersburg, MD, USA) containing 10% fetal bovine serum (FBS) (Gibco) and 1% penicillinstreptomycin solution (Beyotime Biotechnology, Shanghai, China) at 37 o C with 5% CO2. The culture medium was replaced every 2-3 d until cells reached 90% confluence. Cells were passaged after dissociating cells with 0.25% trypsin (Gibco) at room temperature for 2 min. The second passage cells were used for the following experiments.
In vitro cell proliferation assay C3H10T1/2 cells and ATDC5 cells were seeded (2 × 10 3 cells per well) into 96-well plates in triplicates and allowed to adhere overnight. On the following day, the medium was replaced by fresh medium containing cordycepin (Sigma-Aldrich Company). Cultures were incubated for 24, 48, or 72 hours. To determine cell viabilities, 10-l of Cell Counting Kit-8 (CCK8, Dojindo Laboratories) reagent was added to each well and incubated for an additional 4 hours. The absorbance was read at wavelength of 450 nm on an automated plate reader. Wells containing CCK8 reagent without cells were used as blank controls. Cell proliferation was assessed based on the absorbance values according to the manufacturer's protocol.
Chondrogenic differentiation assay
C3H10T1/2 cells were dissociated using 0.25% trypsin and adjusted to a density of 10 5 cells/ml. Cell suspension (2 ml/well) was placed into the center of each well on a 6-well plate. After incubation for 24 h at 37 o C with 5% CO2, the medium was replaced by 2 ml chondrogenic differentiation medium (Gibco) containing dexamethasone (100 nmol/L), ascorbate (50 g/ml), ITS+ Supplement, proline (40 g/ml), and TGF-3 (10 ng/ml). The chondrogenic differentiation medium was refreshed every 3 d.
Hypertrophic differentiation assay
ATDC5 cells were dissociated with 0.25% trypsin and adjusted to a density of 10 5 cells/ml. Cell suspension was placed into the center of each well on a 6-well plate (2 ml/well). After incubation at 37 o C with 5% CO2 for 24 h, the medium was replaced by 2 ml hypertrophic differentiation medium (Gibco) containing dexamethasone (1 nmol/L), ascorbate (50 g/ml), ITS+Supplement, proline (40 g/ml), and triiodothyronine (T3, 100 ng/ml).The hypertrophic differentiation medium was refreshed every 3 d.
Quantitative PCR (qPCR) analysis
Total RNA was isolated from cells using Trizol reagent (Life Technologies). Single-stranded cDNA was prepared from 1 g of total RNA using reverse transcriptase and oligo-dT primer using First Strand cDNA synthesis kit (TaKaRa Biotechnology Co.) according the manufacturer's instructions. Each cDNA (2 l) was subjected to qPCR amplification using gene specific primers (Table S1) 
Western blot analysis
Cells were extracted with cell lysis buffer [50 mM Tris (pH 7.6), 150 mM NaCl, 1% TritonX-100, 1% deoxycholate, 0.1% SDS, 1 mM PMSF, and 0.2% Aprotinin (Beyotime)]. After measuring protein concentration by BCA protein assay (Beyotime), equal protein amounts were mixed with 5× sample buffer (Beyotime) and boiled. These samples were resolved on 10% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and transferred onto PVDF (polyvinylidene fluoride) membrane by using semi-dry transfer method. After blocking in 10% nonfat dry milk in TBST (tris-buffered saline tween-20) for 2 h, blots were incubated with primary antibodies including Col II (rabbit polyclonal 1:500, Abcam), Sox9 (rabbit polyclonal 1:500, Abcam), Runx2 (rabbit polyclonal 1:500, Abcam), Col X (rabbit polyclonal 1:500, Abcam) and GAPDH (rabbit polyclonal 1:1,000, Abcam) at 4 o C overnight. After washing with TBST three times, blots were incubated with goat anti-rabbit secondary antibody (1:2,000, ZSGB-BIO) at room temperature for 1 h. GAPDH was used as loading control.
Glycosaminoglycan (GAG) synthesis analysis by Toluidine blue staining
To demonstrate the deposition of cartilage matrix proteoglycans, representative cultures were collected at indicated time points (day 7, 14, and 28) of induction and sulfated cartilage glycosaminoglycans (GAGs) were measured by Toluidine blue (Beyotime) staining. Cells were fixed in 4% paraformaldehyde for 15 min and stained with Toluidine blue for 5 min. The mean density was normalized to total cell number.
Immunohistochemistry
Cells were fixed in 4% paraformaldehyde for 15 min, washed in phosphate-buffered saline (PBS), and treated with H2O2 (ZSGB-BIO Biotechnology, Beijing, China) for 10 min to inactivate endogenous peroxidase. After treatment with normal goat serum (ZSGB-BIO) at room temperature for 15 min, cells were incubated with primary antibody including Col II (rabbit polyclonal 1:500, Abcam), Sox9 (rabbit polyclonal 1:500, Abcam), Runx2 (rabbit polyclonal 1:500, Abcam) and Col X (rabbit polyclonal 1:500, Abcam) at 4 o C overnight. After washing with PBS, cells were incubated with biotinylated goat anti-rabbit (ZSGB-BIO) secondary antibodies for 30 min followed by washing and incubation with horseradish peroxidase (HRP) conjugated secondary antibody (ZSGB-BIO) for 15 min. The area of the immunocomplex was visualized using chromogen 3, 3'-diaminobenzidine (DAB) as substrate for 5 min. Cells were observed under Olympus fluoresence microscope (IX71). Image-Pro plus 6.0 software was used for image analysis.
Statistics
Statistical significance was determined using SPSS 13.0 and data were presented as mean±standard deviation. *P ＜ 0.05, **P ＜ 0.01, and ***P ＜ 0.001 were regarded as statistically significant.
